ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 2 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - tobramycin - אבקה לשאיפה בקפסולות קשיחות - tobramycin 28 mg - tobramycin - tobramycin - suppressive therapy of chronic pulmonary infection due to pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis.

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole as benzoate - תרחיף - metronidazole as benzoate 25 mg/ml - metronidazole - metronidazole - infections caused by anaerobic bacterias, amebiosis, lambliasis and trichomonas.

ישראל - עברית - Ministry of Health

teva israel ltd - tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - indicated for the treatment of : 1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv.2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease.

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 150 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 300 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.